Non Muscle Invasive Bladder Cancer Pipeline and Clinical Trials Analysis 2023 (Updated): 25+ Companies are working to improve the Treatment of Space

(Albany, United States) As per DelveInsight's assessment, globally, the Non Muscle Invasive Bladder Cancer pipeline constitutes 25+ key companies continuously working towards developing 30+ Non Muscle Invasive Bladder Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Non Muscle Invasive Bladder Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Non Muscle Invasive Bladder Cancer NDA approvals (if any), and product development activities comprising the technology, Non Muscle Invasive Bladder Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

To explore more information on the latest breakthroughs in the Non Muscle Invasive Bladder Cancer Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Non Muscle Invasive Bladder Cancer Pipeline Report
• DelveInsight's Non Muscle Invasive Bladder Cancer Pipeline analysis depicts a robust space with 25+ active players working to develop 30+ pipeline treatment therapies.
• The leading Non Muscle Invasive Bladder Cancer Companies are working in the market include Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, Merck Sharp & Dohme LLC, Medelis Inc, Ferring Pharmaceuticals, FKD Therapies, Cepheid, Protara Therapeutics, Binhui Biopharmaceutical Co., Ltd., Pfizer, and others
• Promising Non Muscle Invasive Bladder Cancer Pipeline Therapies in the various stages of development include PF-06801591, Bacillus Calmette-Guerin, VB4-845 Injection, OH2 injection, TARA-002, ADSTILADRIN, cis-UCA solution, TLD1433 infusion and photodynamic therapy (PDT) treatment, Pembrolizumab Injection, CG0070, and others
• On February 2023, Cepheid has announced drug named Xpert Bladder Cancer Monitor in the market. Bladder cancer is the 5th most common cancer in Europe, with more than 151,000 new cases diagnosed in 2012 (4% of the total). Bladder cancer has the highest recurrence rate of any malignancy, often as high as 70% within 5 years of successful treatment.
• On May 2023, Protara Therapeutics has announced drug named TARA-002 in the market by the phase 2. This study is open-label dose expansion study to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with consomitant Ta) after transurethral resection of bladder tumor (TURBT) and/or biopsy using TARA-002 in adults unable to obtain intravesical Bacillus Calmette-Guérin (BCG), adults who have received at least one dose of intravesical BCG or adults who have received at least one dose of intravesical chemotherapy.
• On June 2023, Pfizer has announced drug named PF-06801591 and Bacillus Calmette-Guerin in the market by the phase 3. The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk (Part A) or was previously treated with BCG (Bacillus Calmette Guerin), a standard treatment for bladder cancer (Part B).

Non Muscle Invasive Bladder Cancer Overview
Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved. Bladder cancer is the 6th most common cancer in the United States. Nearly 81,000 people will be diagnosed in the United States with bladder cancer in 2020. Bladder cancer is more common in males than females.

For further information, refer to the detailed Non Muscle Invasive Bladder Cancer Unmet Needs, click here for Non Muscle Invasive Bladder Cancer Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non Muscle Invasive Bladder Cancer Emerging Drugs Profile
• APL-1202: Asieris Pharmaceuticals
• Pemigatinib: Incyte Corporation
• VAX 014: Vaxiion Therapeutics

Non Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment
There are approx. 25+ Non Muscle Invasive Bladder Cancer companies which are developing the therapies for Non Muscle Invasive Bladder Cancer. The Non Muscle Invasive Bladder Cancer companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. Phase III include, Asieris Pharmaceuticals.

Request a sample and discover the recent advances in Non Muscle Invasive Bladder Cancer Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non Muscle Invasive Bladder Cancer Drugs and Companies
• APL-1202: Asieris Pharmaceuticals
• Nivolumab: Bristol-Myers Squibb
• PF-06801591: Pfizer
• Pemigatinib: Incyte Corporation
• Erdafitinib: Janssen Pharmaceuticals

Non Muscle Invasive Bladder Cancer Market Drivers
• Increase in the number of patients suffering from non-muscle invasive bladder cancer. Approximately 70-75%bladder cancers are non-muscle invasive bladder cancer (NMIBC)
• Development of novel therapies and favorable government policies

Non Muscle Invasive Bladder Cancer Market Barriers
• Identifying the patient population with specific mutations for targeted therapy regimens
• Lack of awareness about the advanced cancer therapies

Non Muscle Invasive Bladder Cancer Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Non Muscle Invasive Bladder Cancer Therapeutics Market include-
Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, Merck Sharp & Dohme LLC, Medelis Inc, Ferring Pharmaceuticals, FKD Therapies, Cepheid, Protara Therapeutics, Binhui Biopharmaceutical Co., Ltd., Pfizer, and others.

Dive deep into rich insights for drugs for Non Muscle Invasive Bladder Cancer Pipeline, click here for Non Muscle Invasive Bladder Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Non Muscle Invasive Bladder Cancer Pipeline Report
• Coverage- Global
• Non Muscle Invasive Bladder Cancer Companies- Bristol-Myers Squibb, Pfizer, Asieris Pharmaceuticals, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Tollys, Merck Sharp & Dohme LLC, Medelis Inc, Ferring Pharmaceuticals, FKD Therapies, Cepheid, Protara Therapeutics, Binhui Biopharmaceutical Co., Ltd., Pfizer, and others.
• Non Muscle Invasive Bladder Cancer Therapies- PF-06801591, Bacillus Calmette-Guerin, VB4-845 Injection, OH2 injection, TARA-002, ADSTILADRIN, cis-UCA solution, TLD1433 infusion and photodynamic therapy (PDT) treatment, Pembrolizumab Injection, CG0070, and others.
• Non Muscle Invasive Bladder Cancer Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Non Muscle Invasive Bladder Cancer Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Non Muscle Invasive Bladder Cancer Executive Summary
3. Non Muscle Invasive Bladder Cancer: Overview
4. Non Muscle Invasive Bladder Cancer Pipeline Therapeutics
5. Non Muscle Invasive Bladder Cancer Therapeutic Assessment
6. Non Muscle Invasive Bladder Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. APL-1202: Asieris Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Pemigatinib: Incyte Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. VAX 014: Vaxiion Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Non Muscle Invasive Bladder Cancer Key Companies
21. Non Muscle Invasive Bladder Cancer Key Products
22. Non Muscle Invasive Bladder Cancer- Unmet Needs
23. Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
24. Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
25. Non Muscle Invasive Bladder Cancer Analyst Views
26. Non Muscle Invasive Bladder Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.